Michael Castagna became CEO of MannKind and joined its board of directors in 2017, bringing 25+ years’ experience in ...
"We're delighted to share that these trials have now been initiated, and really, the progression of the MARITIME program is ...
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
Amgen research and development executive vice-president Jay Bradner said: "Chronic rhinosinusitis with nasal polyps is a ...
Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen shares saw a slight uptick on March 5 as the company shared the news that it has started two critical late-stage ...
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...